Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: A 6-month open-label study

CNS Drugs

Volumn 22, Issue 6, 2008, Pages 519-527

  Trosch, Richard M ^a   Silver, Dee ^b   Bottini, Peter B ^c  

^a Parkinson's Disease and Movement Disorders Center   (United States)

^b Coastal Neurological Group ^*  (United States)

^c Formulation Development Services   (India)

Author keywords

Apomorphine, therapeutic use; Dopamine receptor agonists, therapeutic use; Parkinson's disease, treatment; Subcutaneous

Indexed keywords

APOMORPHINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BRADYCARDIA; CHRONIC DRUG ADMINISTRATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; INCIDENCE; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; OUTPATIENT; PARKINSON DISEASE; PNEUMONIA; PRIORITY JOURNAL; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OUTPATIENTS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 43749088474     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822060-00005     Document Type: Article

References (18)

1. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984 Jun; 107 (Pt 2): 487-506
2. Melamed E, Zoldan J, Galili-Mosberg R, et al. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. J Neural Transm Suppl 1999; 56: 173-83
3. Vaamonde J, Ibanez R, Gudin M, et al. Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients [in Spanish]. Neurologia 2003 Apr; 18 (3): 162-5
4. van Laar T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs 2003; 17 (7): 475-89
5. Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord 2003 Aug; 9 Suppl. 2: S73-81
6. Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol 2004 Aug; 3 (8): 466-74
7. Dewey Jr RB, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001 Sep; 58 (9): 1385-92
8. Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004 Mar 23; 62 (6 Suppl. 4): S12-7
9. Pahwa R, Koller WC, Trosch RM, et al. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007 Jul 15; 258 (1-2): 137-43
10. Pfeiffer RF, Gutmann L, Hull Jr KL, et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2007 Mar; 13 (2): 93-100
11. Apokyn (apomorphine hydrochloride injection) prescribing information. Vernalis Pharmaceuticals Inc., 2006 Jun [online]. Available from URL: http://www.apokyn.com/pdf/APOKYN_PI.pdf [Accessed 2008 Apr 21]
12. Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990 Feb; 53 (2): 96-101
13. Poewe W, Kleedorfer B, Gerstenbrand F, et al. Subcutaneous apomorphine in Parkinson's disease [letter]. Lancet 1988 Apr 23; I (8591): 943
14. Stibe CM, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988 Feb 20; I (8582): 403-6
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42
16. Fahn S, Elson R, UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Calne D, et al., editors. Recent developments in Parkinson's disease. Vol. 2. Florham Park (NJ): Macmillan Healthcare Information, 1987: 153-63
17. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994 Jul; 9 (4): 390-4
18. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004; 21 (11): 687-709